Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 3/15/2019 |
| Start Date: | December 1, 2017 |
| End Date: | August 1, 2040 |
| Contact: | Medical College of Wisconsin Clinical Cancer Center |
| Email: | cccto@mcw.edu |
| Phone: | 414-805-8900 |
This protocol is designed as a long-term follow-up study of patients who will receive
genetically modified autologous CAR-T cells as part of clinical trial at the Medical College
of Wisconsin/ Froedtert Hospital-- Phase 1 Study of CAR-20/19-T Cells in Patients with
Relapsed Refractory B Cell Malignancies.
genetically modified autologous CAR-T cells as part of clinical trial at the Medical College
of Wisconsin/ Froedtert Hospital-- Phase 1 Study of CAR-20/19-T Cells in Patients with
Relapsed Refractory B Cell Malignancies.
The objective is to follow patients receiving CD20/CD19 lentiviral modified CAR-T cells
(CAR-20/19-T cells) from years 2 to 15 post-treatment for persistence of CAR-T cells,
development of secondary malignancies, or other medical complications.
(CAR-20/19-T cells) from years 2 to 15 post-treatment for persistence of CAR-T cells,
development of secondary malignancies, or other medical complications.
Inclusion Criteria:
- All patients who enrolled in the Phase 1 CAR-20/19-T cell study at Froedtert & the
Medical College of Wisconsin.
Exclusion Criteria:
- There are no exclusion criteria for this study.
We found this trial at
1
site
Click here to add this to my saved trials
